Comparing Serum Orexin-A Levels Between Affected and Non-Affected People to Acute Mountain Sickness

Document Type : Research Paper I Open Access I Released under (CC BY-NC 4.0) license

Authors

1 Associate Professor, Department of Exercise Physiology , Faculty of Sports Sciences, Razi University, Kermanshah, Iran

2 Msc of Exercise Physiology, Department of Exercise Physiology, Faculty of Sports Sciences, Razi University, Kermanshah, Iran

10.22049/jassp.2020.26921.1328

Abstract

Aim: Acute mountain sickness occurs generally after ascent to altitudes higher than 2500m and is not related to the physical fitness. The aim of this study was to investigate the serum levels of Orexin-A in people with and without the Acute Mountain Sickness. Methods: For this purpose, 14 men and women subjects participated in this study, voluntarily. All subjects transferred from Tehran to 3700m altitude of mount by the Tochal cable car at 9 am. Then, after 20min of modest hiking, they reach to the Tochal summit shelter at about 3960m altitude. Blood samples collected for the measurement of Orexin-A levels at three times: before the transferring in Tehran, 30min after arriving at altitude, and after 24h staying at altitude. The diagnostic criteria for the acute mountain sickness was a score of at least three from the Lake Louise questionnaire with headache present. Results: Half of the subjects (n=7) affected to acute mountain sickness. The independent sample t-test showed that the subjects with the acute mountain sickness had lower levels of Orexin-A in Tehran, significantly (p=.044). However, the Orexin-A levels of affected and non-affected subjects were not significantly different after 30min and 24h at altitude (p=.08 and p=.10, respectively). There were negative significant correlations between the Lake Louise questionnaire scores and Orexin-A levels in Tehran and at altitude (p=.025 and p=.044, respectively). Conclusions: In conclusion, the serum levels of Orexin-A at low altitude could be consider as a predictive factor for the susceptible people to acute mountain sickness at high altitude. 

Keywords


  1.  

    1. Basnyat B, Murdoch DR. High-altitude illness. Lancet. 2003; 361(9373):1967-74.
    2. Hackett PH, Roach RC. High-altitude illness. N Engl J Med. 2001; 345(2):107-14.
    3. Grant S, MacLeod N, Kay JW, Watt M, Patel S, Paterson A et al. Sea level and acute responses to hypoxia: do they predict physiological responses and acute mountain sickness at altitude? Br J Sports Med. 2002; 36(2):141-6.
    4. MacInnis MJ, Carter EA, Freeman MG, Pandit BP, Siwakoli A, Subedi A et al. A Prospective Epidemiological Study of Acute Mountain Sickness in Nepalese Pilgrims Ascending to High Altitude (4380 m). PLoS One. 2013; 8(10):e75644.
    5. Milledge JS, Thomas PS, Beeley JM, English JS. Hypoxic ventilatory response and acute mountain sickness. Eur Respir J. 1988(10):948-51.
    6. Pesce C, Leal C, Pinto H, Gonzalez G, Maggiorini M, Schneider M et al.Determinants of acute mountain sickness and success on Mount Aconcagua (6962 m). High Alt Med Biol. 2005; 6(2):158-66.
    7. Roach RC, Bärtsch P, Oelz O, and Hackett PH. The Lake Louise acute mountain sickness scoring system. In: Hypoxia and Molecular Medicine, J.R. Sutton, C.S. Houston, and G. Coates, eds. Queen City Press, Burlington, VT (1993); 272–274.
    8. Robert CH, Hackett PH. Frontiers of hypoxia research: acute mountain sickness. J Exp Biol. 2001; 204(Pt 18):3161-70.
    9. Chieffi S, Carotenuto M, Monda V, Valenzano A, Villano I, Precenzano F et al. Orexin System: The Key for a Healthy Life. Front Physiol. 2017; 8:357-65.
    10. Sakurai T, Mieda, M, Tsujino N. The orexin system: roles in sleep/wake regulation. Ann N Y Acad Sci.  2010; 1200:149-61.
    11. Yuan LB, Dong HL, Zhang HP, Zhao RN, Gong G, Chen XM et al. Neuroprotective Effect of Orexin-A Is Mediated by an Increase of Hypoxia-inducible Factor-1 Activity in Rat. Anesthesiology. 2011;114(2):340-54.
    12. Sikder D & Kodadek T. The neurohormone orexin stimulates hypoxia-inducible factor-1 activity. Genes Dev. 2007; 21(22):2995-3005.
    13. Ding H, Liu Q, Hua M, Ding M, Du H, Zhang W et al. Polymorphisms of hypoxia-related genes in subjects susceptible to acute mountain sickness. Respiration. 2011; 81, 236–241.
    14. Zhang JH, Shen Y, Liu C, et al. EPAS1 and VEGFA gene variants are related to the symptoms of acute mountain sickness in Chinese Han population: a cross-sectional study. Mil Med Res. 2020;7(1):35.
    15. Schneider M, Bernasch D, Weymann J, Holle R, Bartsch P. Acute mountain sickness: influence of susceptibility, preexposure, and ascent rate. Med Sci Sports Exerc. 2002; 34(12):1886-91.
    16. Tadibi V, Sheikholeslami-Vatani D, Yousefi B, Abdollahi Shamami N. Factors related to the incidence of Acute Mountain Sickness. Research Sports Sci. 2010; 2(7):13-26. In Persian.
    17. Ziaee V, Yunesian M, Ahmadinejad Z, Halabchi F, Kordi R, Alizadeh R, Afsharjoo HR. Acute mountain sickness in Iranian trekkers around Mount Damavand(5671m) in Iran, Wilderness Environ Med. 2003;14(4):214-9.
    18. Gonggalanzi, Labasangzhu, Nafstad P, et al. Acute mountain sickness among tourists visiting the high-altitude city of Lhasa at 3658 m above sea level: a cross-sectional study. Arch Public Health. 2016;74:23.
    19. Kline DD, Peng YJ, Manalo DJ, Semenza GL, Prabhakar NR. Free in PMC defective carotid body function and impaired ventilatory responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1 alpha. Proc Natl Acad Sci U S A. 2002; 99: 821-826.
    20. Pattinson, K.T., et al. Acute mountain sickness, vitamin C, free radicals, and HIF-1a. Wilderness & environmental medicine. 2005;16 (3): 172–175
    21. Ušaj A, Burnik S. The Influence of High-Altitude Acclimatization on Ventilatory and Blood Oxygen Saturation Responses During Normoxic and Hypoxic Testing. J Hum Kinet. 2016; 50:125-133.